Nine Chapters Capital Management’s AstraZeneca AZN Stock Holding History

Nine Chapters Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-21,500	Closed	-$1.54M	–	944
2014 Q3	$1.54M	Buy	21,500 +16,800	+357%	+$1.23M	0.14%	191
2014 Q2	$349K	Buy	+4,700	New	+$340K	0.03%	674
2013 Q3	–	Sell	-12,300	Closed	-$582K	–	757
2013 Q2	$582K	Buy	+12,300	New	+$626K	0.1%	302

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Nine Chapters Capital Management's AZN Position: Q4 2014 in Review

Nine Chapters Capital Management sold out of AstraZeneca (AZN) in Q4 2014, closing a stake of 21,500 shares — an estimated $1.54M sold.

Nine Chapters Capital Management first reported a position in AZN in Q2 2013 and held it in 3 quarters. The position peaked at $1.54M in Q3 2014. 404 funds tracked by Wall St. Rank hold AZN as of Q4 2014.

Nine Chapters Capital Management reported no remaining AstraZeneca position as of Q4 2014 after selling out during the quarter.
Nine Chapters Capital Management sold 21,500 AstraZeneca shares in Q4 2014, an estimated $1.54M.
Nine Chapters Capital Management first reported a position in AstraZeneca in Q2 2013 and held it in 3 quarters.
Nine Chapters Capital Management's AstraZeneca position peaked at $1.54M in Q3 2014.
404 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2014.

Based on Nine Chapters Capital Management's 13F filing for Q4 2014, filed 9 Feb 2015.